Sponsors (50)
The bill creates clearer labeling and regulatory pathways intended to reduce foodborne pathogens and prevent misleading therapeutic claims, but it imposes substantial compliance costs and delays and narrows which products qualify, potentially raising prices and limiting options for producers.
Farmers and livestock producers can use approved zootechnical substances to reduce foodborne pathogens in food animals, potentially lowering contamination in meat and poultry.
Manufacturers (including small businesses) get a clearer regulatory pathway and explicit labeling rules for zootechnical additives, reducing regulatory uncertainty for product development and commercialization.
Consumers and animal owners are protected from misleading therapeutic claims because labeling is explicitly restricted so products cannot be marketed as disease treatments for animals.
Small businesses and petitioners must submit extensive data and full investigation reports, substantially increasing compliance costs and time to market for new zootechnical substances.
Farmers and livestock producers may face delays in access to beneficial products and higher product prices because zootechnical substances are treated under a food-additive regulatory framework.
Producers could lose access to some potentially useful interventions because the bill's narrow definition (must act solely in the GI tract and excludes certain classes) may exclude classes of zootechnical substances.
Based on analysis of 2 sections of legislative text.
Creates a new regulatory category for certain animal feed ingredients, treats them as food additives, adds data and labeling requirements, and prohibits disease-treatment claims.
Creates a new regulatory category for certain animal feed ingredients called a “zootechnical animal food substance,” defines what qualifies, and treats those substances as food additives under existing federal law. It requires petitioners to supply specific data showing intended effects and amounts, adds labeling requirements that forbid disease-treatment claims, allows limited structure/function claims, and makes missing required labeling a misbranding violation. The law also clarifies HHS may exclude some substances by rule and cannot require anyone to use these substances.
Introduced March 18, 2025 by Nicholas A. Langworthy · Last progress March 18, 2025